Loading organizations...
§ Private Profile · South San Francisco, CA, USA
Clinical-stage biotechnology company developing engineered T-cell immunotherapies to treat cancer, combining innate and adaptive immunity.
Based in San Francisco, California, CERo Therapeutics is a clinical-stage biotechnology company developing engineered T-cell immunotherapies that combine innate and adaptive immunity to treat hematological and solid tumor cancers. The enterprise accumulated $45 million in private venture funding, including a $43 million round in November 2019, before transitioning to the public markets. The company went public on the Nasdaq exchange under the ticker CERO through a 2023 merger with Phoenix Biotech Acquisition Corp, establishing a pro forma equity capitalization of $145 million and a pre-money equity value of $50 million. The firm's proprietary autologous cell-based therapies integrate traits of macrophages and dendritic cells with T cells, advancing lead product candidate CER-1236 toward clinical trials. CERo Therapeutics was founded in 2016 by Dr. Daniel Corey, Jordan Corey, and Dr. Larry Corey, an alumnus of Juno Therapeutics and Vir Biotechnology.
Cero Therapeutics has raised $40.0M across 1 funding round.
Cero Therapeutics has raised $40.0M in total across 1 funding round.
Cero Therapeutics has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series A in March 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 18, 2020 | $40M Series A | — | Altitude Life Science Ventures, Robert Nelsen, Hongshan Capital Group (Sequoia Capital China), Richard Klausner, Milky WAY Investments | Announced |
Cero Therapeutics has raised $40.0M in total across 1 funding round.
Cero Therapeutics's investors include Altitude Life Science Ventures, Robert Nelsen, Hongshan Capital Group (Sequoia Capital China), Richard Klausner, Milky Way Investments.